Table 4.
Univariate analysis for long-term carbapenem therapy (>8 days).
| Variable | Short-Term Carbapenem Therapy (<7 Days) n = 233 (Episodes) |
Long-Term Carbapenem Therapy (>8 Days) n = 286 (Episodes) |
p-Value |
|---|---|---|---|
| AST intervention | 137 (58.8) | 174 (60.8) | 0.637 |
| Age | 72.0 (24.0–94.0) | 70 (24.0–92.0) | 0.049 * |
| eGFR (mL/min/1.73 m2) | 61.1 (5.4–318.0) | 68.3 (3.7–268.6) | 0.206 |
| Granulocytes (/µL) | 456.0 (0.0–10,510) | 162.0 (0.0–50,300.0) | 0.005 * |
| Hypotension | 23 (9.9) | 19 (6.6) | 0.180 |
| Outpatient onset | 33 (14.2) | 60 (21.0) | 0.044 * |
| Diabetes mellitus | 19 (8.2) | 39 (13.6) | 0.049 * |
| COPD | 1 (0.4) | 14 (4.9) | 0.002 * |
| Medical device | |||
| Central venous catheter | 107 (45.9) | 122 (42.7) | 0.456 |
| Ventilator | 5 (2.1) | 5 (1.7) | 0.743 |
| Indwelling urinary catheter | 72 (30.9) | 58 (20.3) | 0.005 * |
| FUO | 130 (55.8) | 129 (45.1) | 0.015 * |
| MDI | 45 (19.3) | 61 (21.3) | 0.571 |
| CDI | 58 (24.9) | 96 (33.6) | 0.031 * |
| Hematologic disease | |||
| Acute myeloid leukemia | 55 (23.6) | 118 (41.3) | <0.001 * |
| Myelodysplastic syndrome | 27 (11.6) | 35 (12.2) | 0.820 |
| Acute lymphocytic leukemia | 11 (4.7) | 12 (4.2) | 0.772 |
| Malignant lymphoma | 82 (35.2) | 73 (25.5) | 0.017 * |
| Multiple myeloma | 28 (12.0) | 14 (4.9) | 0.003 * |
| Aplastic anemia | 9 (3.9) | 16 (5.6) | 0.359 |
| Chemotherapy within 3 weeks | 151 (64.8) | 190 (66.4) | 0.698 |
| AHSCT | 19 (8.2) | 17 (5.9) | 0.324 |
| Blood culture (two sets) before starting antibiotics | 155 (66.5) | 209 (73.1) | 0.105 |
| Blood culture positivity | 54 (23.2) | 71 (24.8) | 0.662 |
| ESBL and AmpC | 16 (6.9) | 37 (68.9) | 0.023 * |
Number (%) or median (interquartile range). Abbreviations are as follows: AST, antimicrobial stewardship team; eGFR, estimated glomerular filtration rate; COPD, chronic obstructive pulmonary disease; FUO, fever of unknown origin; MDI, microbial documented infection; CDI, clinical documented infection; AHSCT, autologous hematopoietic stem cell transplantation; ESBL, Extended spectrum β-lactamases. * p < 0.05.